Methods and systems for modulating hormones and related methods, agents and compositions
AssigneesCalifornia Institute of Technology, The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs
InventorsWilliam A. Goddard, III, Mark Menna, Stephen Pandol, Ravinder Abrol
Life of this patent
Estimating the term…
Abstract
Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
Claims12
A method for modulating release of a bitter taste receptor mediated metabolic hormone in an individual, the method comprising:
- administering to the individual one or more GI bitter taste receptor ligands selected from the group consisting of 6-n-propylthiouracil, phenylthiocarbamide, denatonium benzoate, Glycyrrhizic acid ammonium salt, Epigallocatechin gallate, Hyperforin, Berberine chloride, Coptisine Chloride, Allyl methyl sulfide, Rottlerin, Curcumin, Ellagic acid, Embelin and/or a derivative thereof, wherein the one or more GI bitter taste receptor ligands are conjugated with a complementary molecule and are configured for interfering with systemic absorption and release of the one or more GI bitter taste receptor ligands, in an effective amount to allow binding of the one or more GI bitter taste receptor ligands to the one or more GI bitter taste receptors in the individual, the binding resulting in modulating release of the bitter taste receptor-mediated metabolic hormone, wherein the metabolic hormone is GLP-1, PYY and/or CCK, wherein the administering is performed by enteral administration.
A method for activating a target bitter taste receptor in an individual, the method comprising:
- administering to the individual an effective amount of one or more bitter tastant ligands that are conjugated with a complementary molecule, wherein the complementary molecule is configured for interfering with systemic absorption and release of the bitter tastant receptor ligand, wherein the administering is performed by enteral administration.
Dependencies are inferred from the claim text.